Basel, Switzerland (ots/PRNewswire) - Ten abstracts providing new analyses of data from six major Phase III renal anaemia studies for MIRCERA(R) will be published/presented at the upcoming 40th Annual Meeting of the American Society of Nephrology (ASN) in San Francisco on 2 - 5 November. Among the highlights will be new analyses from 'maintenance' studies ...
Shire Pharmaceuticals Group Plc
Philadelphia (ots/PRNewswire) - At the U.S. Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee meeting today, the majority of members voted to recommend the use of phosphate binders, including Shire Pharmaceuticals' non-calcium FOSRENOL(R) (lanthanum carbonate), to treat ...
Amsterdam (ots/PRNewswire) - Avantium, a leading technology company servicing the oil, chemicals and pharmaceutical industries, announces the three-year extension of the strategic research collaboration with BP, one of the world's largest energy companies. Avantium provides innovative, high value-added R&D services and tools to the energy, chemicals and pharmaceutical industries, and has a long standing ...
Irvine, California (ots/PRNewswire) - - Conference Calls to Answer Questions About Stockholder Meeting October 23 IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced the interim tabulation results of the special stockholders meeting held on October 11, 2007 and adjourned to October 23, 2007. Prior to October 11, 2007, approximately 2,555,000 shares, 36 percent of the shares ...
Vienna, Austria (ots/PRNewswire) - Valdoxan(R) (agomelatine), the first melatonergic antidepressant, is an effective, long-term treatment for Major Depressive Disorder (MDD) according to new data presented today at the European College of Neurospsychopharmacology (ECNP) annual congress. The new international ...
Calgary, Canada (ots/PRNewswire) - - Novel ApoA-I/HDL Raising Drug, RVX-208, to be Featured in Oral Presentation Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce that tommorrow it is making an oral presentation highlighting key scientific data of its lead clinical molecule, RVX-208, at the International Atherosclerosis Society (IAS) Workshop on HDL. The presentation titled "A novel drug that ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of stockholders it called to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The special meeting of stockholders was held at ...
Leuven, Belgium (ots/PRNewswire) - - EUFAMI Survey Shows Carers Across Europe Believe in Remission as a Realistic Treatment Goal for Many People Living With Schizophrenia A large majority of families who care for someone with schizophrenia are confident that many people with the disease can lead ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies. This acquisition significantly increases Wyeth's already ...
Pittsburgh (ots/PRNewswire) - Mylan (NYSE: MYL) announced today that it has completed its acquisition of Merck KGaA's generics business ("Merck Generics") to become one of the largest quality generics and specialty pharmaceuticals companies in the world. Mylan and Merck KGaA initially announced the signing of a definitive agreement under which Mylan would acquire Merck Generics for EUR 4.9 billion (US$6.8 billion) ...
Pittsburgh (ots/PRNewswire) - Mylan Inc. (NYSE: MYL) today announced the appointment of Rajiv Malik as Executive Vice President in charge of Global Technical Operations. Mr. Malik has served in a similar capacity for Mylan since the Company acquired a controlling stake in Matrix Laboratories Limited (Matrix), where he is Chief Executive Officer, in ...
Pittsburgh (ots/PRNewswire) - - Promoted from Head of North America Mylan Inc. (NYSE: MYL) today announced the appointment of Heather Bresch as Chief Operating Officer. Ms. Bresch served previously as Head of North America and Chief Integration Officer. As Chief Operation Officer, Ms. Bresch will be responsible for Mylan's global commercial and technical operations, strategic planning, business development and ...
Pittsburgh (ots/PRNewswire) - Mylan Inc. (NYSE: MYL) today announced the appointment of Didier Barret to the position of President, EMEA (Europe, Middle East and Africa) following the completion of Mylan's acquisition of Merck's Generics Group today. At Merck Generics, M. Barret most recently served as Region Director, EMEA, reporting to the CEO. He was ...
All Eyes on Glaucoma(TM) Campaign
London (ots/PRNewswire) - - Global Advocacy Groups Launch Joint Effort to Preserve Eyesight of Millions At-Risk for Glaucoma Results of a new international survey reveal that eye exams are being ignored by many aged over 40. Only two fifths of respondents had visited an eye specialist in the last year to have their eyes checked, even though twice as many ...
Paris (ots/PRNewswire) - - New Design Offers Greater Flexibility in the Management of Patients With Complex Atherosclerosis Boston Scientific Corporation (NYSE: BSX) announced today that the Apex(TM) Monorail and Over-The-Wire (OTW) PTCA dilatation catheters have received CE Mark approval. Both Monorail and OTW catheters are available in two designs to ...
European Liver Patients Association (ELPA)
Brussels, Belgium (ots/PRNewswire) - - European Liver Patients Association Urges People at Risk to get Tested! A report(1) released today by the Eurasian Harm Reduction Network (EHRN)(i) highlights the significant inconsistencies that exist in hepatitis C (HCV) diagnosis and treatment across Europe and ...
London (ots/PRNewswire) - Eisai Limited, the licence holder of Aricept(R) (donepezil hydrochloride) and Pfizer Limited, its co-promotion partner, announced today that Eisai has applied to the Court of Appeal for permission to appeal the recent High Court ruling on the process by which the National Institute for Health and Clinical Excellence (NICE) reached its ...
London (ots/PRNewswire) - - For the Attention of Business and Healthcare Editors Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that the Company established its pharmaceutical marketing subsidiary, Eisai SA/NV in Belgium. Eisai SA/NV is owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya). ...
Cambridge, England (ots/PRNewswire) - - New Approach in the Development of Opioid-Based Pain Management Therapy Improves Bowel Function The oral prolonged-release (PR) oxycodone / naloxone combination tablet reduces opioid-induced bowel dysfunction in patients with chronic severe pain compared to ...
Barcelona, Spain (ots/PRNewswire) - - Abstract no: 2030, Being Presented at ECCO in the "Proffered Papers: Breast Cancer - Early Disease" Session in the Forum, Starting at 09.00am on Wednesday 26th September 2007 - For non-US Media Only New data show that the addition of Herceptin(R) (trastuzumab) ...
Boxmeer, The Netherlands and London (ots/PRNewswire) - Nobilon International B.V., part of Organon, the human health care business unit of Akzo Nobel, and Protherics PLC, the international biopharmaceutical company focused on critical care and cancer, today announced that Nobilon has licensed Protherics' CoVaccine HT(TM) adjuvant for use in pandemic influenza ...
Boxmeer, The Netherlands (ots/PRNewswire) - A consortium of experts in the field of human virus research and vaccine development have joined forces to develop a novel pandemic influenza vaccine as a potential emergency vaccination. The four-year project has been awarded a grant of EUR3.5 million from the European Union to help fund the research and the development ...
Siemens Medical Solutions Diagnostics
Tarrytown, New York (ots/PRNewswire) - - Advanced Network-Ready Diabetes Analysis for Better Patient Management Siemens Medical Solutions Diagnostics (www.siemens.com/diagnostics) today announced the launch of the DCA Vantage(TM) Analyzer, a point-of-care (POC) diabetes patient management platform ...
Barcelona, Spain (ots/PRNewswire) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ -- - 5 Year Data Confirm Superiority of Xeloda Over the Mayo Clinic Regimen in Treating Colon Cancer Five-year follow-up data from the X-ACT trial presented today ...
Barcelona, Spain (ots/PRNewswire) - Abstract no: 1LB, being presented at ECCO "Gastrointestinal malignancies - colorectal cancer 1" session in room 110, starting at 09.00 on Tuesday 25 September 2007 BARCELONA, Spain, September 25 /PRNewswire/ -- - 5 Year Data Confirm Superiority of Xeloda Over the Mayo Clinic Regimen in Treating Colon Cancer Five-year follow-up data from the X-ACT trial presented today ...
Barcelona, Spain (ots/PRNewswire) - - Largest Series of Patients With Successful Surgery Reported in Large, Prospective Clinical Trial - Abstract no: 3020, Being Presented at ECCO in Room 115-116, Starting at 12:15 on Monday 24th September 2007 - For non-US Media Only New data from the large international First BEAT trial unveiled today at the ...
Barcelona (ots/PRNewswire) - - For Medical and Healthcare Media Only - FOR INTERNATIONAL JOURNALISTS - NOT FOR US MEDIA - Data Highlight the Need for More Positive Conversations Through Better Communication, Training and Use of Effective Treatments A devastating moment for a woman undergoing ...
Collegeville, Pennsylvania (ots/PRNewswire) - - European Committee Issues Negative Opinion on MYLOTARG(R) for Acute Myeloid Leukemia; Wyeth Plans to Appeal Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Callisto Pharmaceuticals. Inc.
New York (ots/PRNewswire) - Callisto Pharmaceuticals, Inc. (Amex: KAL; FWB: CA4), a developer of new drug treatments in the fight against cancer and gastrointestinal disorders and diseases, announced today that complete enrollment of its Phase II clinical trial of Atiprimod to treat low to intermediate grade neuroendocrine carcinoma (advanced carcinoid cancer) ...
Honolulu, Hawaii (ots/PRNewswire) - - Protelos(R) Relaunches Bone Formation and Increases Bone Volume in Patients on Long Term Bisphosphonate Treatment Protelos(R) (strontium ranelate) stimulates bone formation and increases bone volume by 30% in high fracture risk patients who have been on long term ...